Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Sickle Cell Disease: Current Treatment and Emerging Therapies
source: The American Journal of Managed Care (AJMC)
year: 2019
authors: Lynne D. Neumayr, Carolyn C. Hoppe, Clark Brown
summary/abstract:Sickle cell disease (SCD) is among the most common genetic diseases in the United States, affecting approximately 100,000 people. In the United States, SCD is characterized by a shortened life expectancy of only about 50 years in severe subtypes, significant quality-of-life impairments, and increased healthcare utilization and spending. SCD is characterized by chronic hemolytic anemia, vaso-occlusion, and progressive vascular injury affecting multiple organ systems. The pathophysiology is directly related to polymerization of deoxygenated hemoglobin, leading to a cascade of pathologic events including erythrocyte sickling, vaso-occlusion, tissue ischemia, and reperfusion injury as well as hemolysis, abnormal activation of inflammatory and oxidative pathways, endothelial dysfunction, increased oxidative stress, and activation of coagulation pathways.
These multifactorial abnormalities have both acute and chronic clinical consequences across multiple organ systems, including acute pain episodes, chronic pain syndromes, acute chest syndrome, anemia, stroke and silent cerebral infarcts, cognitive dysfunction, pulmonary hypertension, and a wide range of other clinical consequences.
organization: UCSF Benioff Children’s Hospital Oakland, USA; Global Blood Therapeutics, USA; Emory University, USA; Children’s Healthcare of Atlanta, Scottish Rite Hospital, USAread more
Related Content
-
Initial results from a cohort in a phase 2a study (GBT440-007) evaluating adolescents with sickle cell disease treat...Sickle cell disease (SCD) is a genetic d...
-
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
-
Emmaus Medical, Inc. Selects AmerisourceBergen to Support the Launch of EndariTM (L-glutamine oral powder)AmerisourceBergen, a global healthcare s...
-
Muscle Structural, Functional and Energetic Benefits of Endurance Exercise Training in Sickle Cell DiseaseSickle cell disease (SCD) patients displ...
-
These patients had sickle-cell disease. Experimental therapies might have cured themScientists have long known what causes s...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with Cardinal Health to solidify distribution net...Emmaus Life Sciences, Inc. announces...
-
Miai & Ama Talk About Sickle Cell Diseasehttps://www.youtube.com/watch?v=7bUFGux-...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.